Pfizer, ConcertAI Partner on Precision Oncology

The collaboration will conduct novel synthetic control arm and prospective RWD outcomes study designs for both pre- and post-approval therapeutics with the goal of speeding up study completion for Pfizer‘s investigational therapies and commercialized therapeutics used to treat solid tumors and hematologic malignancies. 

Read More